Anti-lymphocyte therapy successfully controls late "cholestatic" rejection in pediatric liver transplant recipients

Clinical Transplantation

Volumn 25, Issue 6, 2011, Pages

  Kerkar, N ^a,b   Morotti, R A ^b   Iyer, K ^a   Arnon, R ^a   Miloh, T ^a,b   Sturdevant, M ^a,c   Suchy, F ^a   Florman, S ^a   Emre, S ^a,d  

^a Recanati Miller Transplant Institute   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d Yale New Haven Transplantation Center   (United States)

Author keywords

Adolescents; Anti lymphocyte treatment; Cholestasis; Graft survival; Non adherence

Indexed keywords

AMINOTRANSFERASE; AZATHIOPRINE; BILIRUBIN; COTRIMOXAZOLE; DACLIZUMAB; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; ZENEPAX;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CHILD; CHOLESTASIS; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION; LIVER TRANSPLANTATION; MALE; PEDIATRIC SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; CHILD; CHILD, PRESCHOOL; CHOLESTASIS; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER TRANSPLANTATION; MALE; MUROMONAB-CD3; PROGNOSIS; RETROSPECTIVE STUDIES; TACROLIMUS; YOUNG ADULT;

EID: 83555163822     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2011.01494.x     Document Type: Article

References (19)

1. Ng VL, Fecteau A, Shepherd R et al. Outcomes of 5-year survivors of pediatric liver transplantation: report on 461 children from a North American multicenter registry. Pediatrics 2008: 122: e1128.
2. Soltys KA, Mazariegos GV, Squires RH, Sindhi RK, Anand R. Late graft loss or death in pediatric liver transplantation: an analysis of the SPLIT database. Am J Transplant 2007: 7: 2165.
3. Platz KP, Mueller AR, Zytowski M, Lemmens P, Lobeck H, Neuhaus P. Management of acute steroid-resistant rejection after liver transplantation. World J Surg 1996: 20: 1052; discussion 1058-9.
4. Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997: 25: 658.
5. Kerkar N, Morotti RA, Madan RP et al. The changing face of post-transplant lymphoproliferative disease in the era of molecular EBV monitoring. Pediatr Transplant 2010: 14: 504.
6. Miloh T, Annunziato R, Arnon R et al. Improved adherence and outcomes for pediatric liver transplant recipients by using text messaging. Pediatrics 2009: 124: e844.
7. Suriawinata A, Rosencrantz R, Shneider B, Emre S, Thung SN. A 12-year-old boy with chronic hepatitis C cirrhosis and posttransplantation hepatitis. Semin Liver Dis 2001: 21: 573.
8. Aydogan C, Sevmis S, Aktas S, Karakayali H, Demirhan B, Haberal M. Steroid-resistant acute rejections after liver transplant. Exp Clin Transplant 2010: 8: 172.
9. Schmitt TM, Phillips M, Sawyer RG et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci 2010: 55: 3224.
10. Kerkar N, Hadzic N, Davies ET et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998: 351: 409.
11. Aw MM, Verma A, Rela M, Heaton N, Mieli-Vergani G, Dhawan A. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transpl 2008: 14: 1303.
12. Gouw AS, Van Den Heuvel MC, Van Den Berg AP, Slooff MJ, De Jong KP, Poppema S. The significance of parenchymal changes of acute cellular rejection in predicting chronic liver graft rejection. Transplantation 2002: 73: 243.
13. Solomon H, Gonwa TA, Mor E et al. OKT3 rescue for steroid-resistant rejection in adult liver transplantation. Transplantation 1993: 55: 87.
14. Munda R, Hutchins M, First MR, Carey M, Schroeder T, Alexander JW. Infection in OKT3-treated patients receiving additional antirejection therapy. Transplant Proc 1989: 21: 1763.
15. Bijleveld CG, Klompmaker IJ, Van Den Berg AP et al. Incidence, risk factors, and outcome of antithymocyte globulin treatment of steroid-resistant rejection after liver transplantation. Transpl Int 1996: 9: 570.
16. Goldstein G, Kremer AB, Barnes L, Hirsch RL. OKT3 monoclonal antibody reversal of renal and hepatic rejection in pediatric patients. J Pediatr 1987: 111: 1046.
17. Demirag A, Kalayci M, Ekci B, Gulcelik T, Gokce O. Sirolimus for rescue of steroid and anti-thymocyte globulin-resistant recurrent acute rejection after liver transplantation: report of one case. Transplant Proc 2009: 41: 435.
18. Orr DW, Portmann BC, Knisely AS et al. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005: 37: 4373.
19. Chariat MN, Erren M, Chariat M, Deng M, Wolters HH, Dietl KH. Basiliximab in the therapy of acute rejection after organ transplantation. Transplant Proc 2001: 33: 2380.